Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.
作者： A. HILLARP , F. BAGHAEI , I. FAGERBERG BLIXTER , K. M. GUSTAFSSON , L. STIGENDAL
DOI: 10.1111/J.1538-7836.2010.04098.X
关键词: Rivaroxaban 、 Factor Xa Inhibitor 、 Pharmacology 、 Antithrombin 、 Prothrombinase 、 Thrombin 、 Partial thromboplastin time 、 Prothrombin time 、 Chemistry 、 Blood coagulation test
摘要: Introduction: Rivaroxaban is an oral direct factor Xa inhibitor developed for prophylaxis and treatment of thromboembolic disorders. Laboratory monitoring not necessary but the dose dependent effects on common reagents assay procedures are largely unknown. Objectives: To investigate effect rivaroxaban commonly used coagulation assays. Material Methods: was added to plasma from healthy subjects in concentration range 0 -1000 μg/L analyzed using different activated partial thromboplastin time (APTT), prothrombin (PT), antithrombin, fibrinogen protein C (APC) resistance Results: At expected peak clinical use, APTTs were almost invariably prolonged at lower concentrations weak. The needed double APTT varied between 389 ±106 617 ±149 reagents. PT assays showed a marked degree difference. In general, Quick type more sensitive compared Owren results antithrombin reagent with Xa-based being estimated increase 0.09 IU/mL per 100 rivaroxaban. There only minor based thrombin APTT-based APC affected manner whereas activation prothrombinase level unaffected. Conclusions: Different assays, even within group, display variable by therapeutic
core.ac.uk
researchgate.net 
sci-hub.se 参考文章(17)
Angela Menschiek-Lundin, Karin Wåhlander, Tomas Lindahl, Christer Mattsson, Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample. Thrombosis and Haemostasis. ,vol. 86, pp. 611- 615 ,(2001) , 10.1055/S-0037-1616094
Dagmar Kubitza, Michael Becka, Angelika Roth, Wolfgang Mueck, Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects Current Medical Research and Opinion. ,vol. 24, pp. 2757- 2765 ,(2008) , 10.1185/03007990802361499
W. Mueck, M. Becka, D. Kubitza, B. Voith, M. Zuehlsdorf, Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects. principles and practice of constraint programming. ,vol. 45, pp. 335- 344 ,(2007) , 10.5414/CPP45335
Jochen Graff, Nils von Hentig, Frank Misselwitz, Dagmar Kubitza, Michael Becka, Hans-Klaus Breddin, Sebastian Harder, Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet‐Induced Thrombin Generation and Prothrombinase Activity1 The Journal of Clinical Pharmacology. ,vol. 47, pp. 1398- 1407 ,(2007) , 10.1177/0091270007302952
Bengt I Eriksson, Daniel J Quinlan, Jeffrey I Weitz, Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development Clinical Pharmacokinectics. ,vol. 48, pp. 1- 22 ,(2009) , 10.2165/0003088-200948010-00001
Wolfgang Mueck, Bengt I Eriksson, Kenneth A Bauer, Lars Borris, Ola E Dahl, William D Fisher, Michael Gent, Sylvia Haas, Menno V Huisman, Ajay K Kakkar, Peter Kälebo, Louis M Kwong, Frank Misselwitz, Alexander G G Turpie, Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban — an Oral, Direct Factor Xa Inhibitor — in Patients Undergoing Major Orthopaedic Surgery Clinical Pharmacokinectics. ,vol. 47, pp. 203- 216 ,(2008) , 10.2165/00003088-200847030-00006
Sebastian Harder, Jeannine Parisius, Bettina Picard-Willems, Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications. Thrombosis Research. ,vol. 123, pp. 396- 403 ,(2008) , 10.1016/J.THROMRES.2008.05.010
Dagmar Kubitza, Michael Becka, Georg Wensing, Barbara Voith, Michael Zuehlsdorf, Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects. European Journal of Clinical Pharmacology. ,vol. 61, pp. 873- 880 ,(2005) , 10.1007/S00228-005-0043-5
Xia Zhao, Peihong Sun, Ying Zhou, Yuwang Liu, Huilin Zhang, Wolfgang Mueck, Dagmar Kubitza, Richard J. Bauer, Hong Zhang, Yimin Cui, Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. British Journal of Clinical Pharmacology. ,vol. 68, pp. 77- 88 ,(2009) , 10.1111/J.1365-2125.2009.03390.X
D KUBITZA, M BECKA, B VOITH, M ZUEHLSDORF, G WENSING, Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clinical Pharmacology & Therapeutics. ,vol. 78, pp. 412- 421 ,(2005) , 10.1016/J.CLPT.2005.06.011